Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OKYONASDAQ:TELONYSE:VHAQNASDAQ:VYNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOKYOOKYO Pharma$1.87+1.1%$1.39$0.81▼$1.98$63.27M-0.38131,513 shs29,655 shsTELOTelomir Pharmaceuticals$2.10+1.4%$2.72$1.98▼$8.40$62.50M0.17138,403 shs205,839 shsVHAQViveon Health Acquisition$11.00$11.00$0.00▼$12.48$62.26M-0.112 shs99 shsVYNEVYNE Therapeutics$0.97-1.0%$1.47$0.96▼$4.30$14.68M1.76113,137 shs115,734 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOKYOOKYO Pharma+5.71%+12.12%+19.35%+60.87%+41.22%TELOTelomir Pharmaceuticals-1.43%-2.82%-16.87%-47.06%-66.77%VHAQViveon Health Acquisition0.00%0.00%0.00%0.00%+10.00%VYNEVYNE Therapeutics-2.50%-2.50%-32.29%-61.00%-62.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOKYOOKYO Pharma2.652 of 5 stars3.55.00.00.02.21.70.0TELOTelomir Pharmaceuticals2.0046 of 5 stars3.81.00.00.01.80.00.6VHAQViveon Health AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AVYNEVYNE Therapeutics2.7264 of 5 stars3.53.00.00.03.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOKYOOKYO Pharma 3.00Buy$7.00274.33% UpsideTELOTelomir Pharmaceuticals 3.50Strong Buy$15.00614.29% UpsideVHAQViveon Health Acquisition 0.00N/AN/AN/AVYNEVYNE Therapeutics 3.00Buy$6.25547.67% UpsideCurrent Analyst Ratings BreakdownLatest VYNE, OKYO, TELO, and VHAQ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/25/2025VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.75 ➝ $4.503/6/2025VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.75 ➝ $5.75(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOKYOOKYO PharmaN/AN/AN/AN/A($0.20) per shareN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/AVHAQViveon Health AcquisitionN/AN/AN/AN/AN/AN/AVYNEVYNE Therapeutics$605K24.26N/AN/A$6.36 per share0.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOKYOOKYO Pharma-$16.83MN/A0.00N/AN/AN/AN/AN/AN/ATELOTelomir Pharmaceuticals-$16.53M-$0.42N/AN/AN/AN/A-1,170.58%-832.67%8/12/2025 (Estimated)VHAQViveon Health Acquisition-$610KN/A0.00∞N/AN/AN/AN/AN/AVYNEVYNE Therapeutics-$28.45M-$0.99N/AN/AN/A-6,896.55%-43.73%-38.55%8/13/2025 (Estimated)Latest VYNE, OKYO, TELO, and VHAQ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025TELOTelomir Pharmaceuticals-$0.10-$0.07+$0.03-$0.07N/AN/A5/8/2025Q1 2025VYNEVYNE Therapeutics-$0.29-$0.20+$0.09-$0.20$0.05 million$0.20 million3/6/2025Q4 2024VYNEVYNE Therapeutics-$0.31-$0.28+$0.03-$0.28$0.14 million$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOKYOOKYO PharmaN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/AVHAQViveon Health AcquisitionN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOKYOOKYO PharmaN/A0.28N/ATELOTelomir PharmaceuticalsN/A1.941.94VHAQViveon Health AcquisitionN/AN/AN/AVYNEVYNE TherapeuticsN/A5.815.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOKYOOKYO Pharma2.97%TELOTelomir PharmaceuticalsN/AVHAQViveon Health Acquisition22.14%VYNEVYNE Therapeutics83.78%Insider OwnershipCompanyInsider OwnershipOKYOOKYO Pharma40.46%TELOTelomir PharmaceuticalsN/AVHAQViveon Health Acquisition75.27%VYNEVYNE Therapeutics4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOKYOOKYO Pharma733.84 million20.15 millionNot OptionableTELOTelomir Pharmaceuticals129.76 millionN/AN/AVHAQViveon Health Acquisition25.66 million1.40 millionNot OptionableVYNEVYNE Therapeutics3015.21 million14.04 millionNot OptionableVYNE, OKYO, TELO, and VHAQ HeadlinesRecent News About These CompaniesVYNE Therapeutics First Quarter 2025 Earnings: Beats ExpectationsMay 12, 2025 | finance.yahoo.comVYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comVYNE Therapeutics' Psoriasis Drug Trial Halted By FDA Over Toxicity Concerns; Stock Down.April 27, 2025 | nasdaq.comVYNE Therapeutics Inc. Faces FDA Clinical Hold on VYN202 Phase 1b Trial for Plaque PsoriasisApril 27, 2025 | nasdaq.comAnalysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and VYNE Therapeutics (VYNE)April 26, 2025 | markets.businessinsider.comVYNE Therapeutics Inc.: VYNE Therapeutics Provides Update on VYN202 ProgramApril 25, 2025 | finanznachrichten.deVYNE shares tumble after FDA clinical hold on psoriasis drug studyApril 25, 2025 | za.investing.comVyne Crashes After Safety Signal in Dogs Puts Hold on Clinical Trial of Plaque PsoriasisApril 25, 2025 | biospace.comFDA puts Vyne in a twist, slapping hold on psoriasis trial over testicular toxicity concernsApril 25, 2025 | fiercebiotech.comFDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On HoldApril 25, 2025 | benzinga.comVYNE Therapeutics Provides Update on VYN202 ProgramApril 25, 2025 | globenewswire.comArtiva Biotherapeutics, Inc.: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical OfficerApril 9, 2025 | finanznachrichten.deArtiva Biotherapeutics Names New Chief Medical OfficerApril 8, 2025 | marketwatch.comVYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2025 | markets.businessinsider.comVYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2025 | globenewswire.comH.C. Wainwright Sticks to Their Buy Rating for Lineage Therap (LCTX)March 12, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Lexicon Pharmaceuticals (LXRX) and Xtant Medical Holdings (XTNT)March 7, 2025 | markets.businessinsider.comVYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 7, 2025 | finance.yahoo.comVYNE Therapeutics reports Q4 EPS (28c) vs (20c) last yearMarch 6, 2025 | markets.businessinsider.comVYNE Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)March 6, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVYNE, OKYO, TELO, and VHAQ Company DescriptionsOKYO Pharma NASDAQ:OKYO$1.87 +0.02 (+1.08%) Closing price 03:59 PM EasternExtended Trading$1.76 -0.11 (-5.61%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Telomir Pharmaceuticals NASDAQ:TELO$2.10 +0.03 (+1.45%) Closing price 04:00 PM EasternExtended Trading$2.10 0.00 (-0.24%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.Viveon Health Acquisition NYSE:VHAQ$11.00 0.00 (0.00%) As of 01/30/2025Viveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC.VYNE Therapeutics NASDAQ:VYNE$0.96 -0.01 (-1.03%) Closing price 04:00 PM EasternExtended Trading$0.99 +0.03 (+2.80%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
